The Mouse Tumor Models Resource (MTMR) was established to: 1) facilitate translational research with the use of animal models for preclinical studies, and 2) consolidate animal expertise for in vivo studies using xenograft and transgenic models. The resource maintains a breeding colony of Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice and has established a tumor bank representing prostate cancer progression in TRAMP as well as several other widely used models of prostate cancer including the CWR22 model, HiMyc model, PBCre4VPten. In addition to prostate cancer models, MTMR also has a sarcoma model and a developing transgenic model of pancreatic cancer. The Resource has expertise in establishing xenografts from clinical samples and routinely grafts human cancer samples subcutaneously or under the renal capsule. MTMR also treats cohorts of animals, tracks tumor growth, and performs tissue procurement and post collection processing for histology and molecular analysis. MTMR offers investigators expertise in all standard small animal surgeries and procedures, including establishment of tumor xenograft (subcutaneous and subrenal), injections (iv, subQ, ip, intracardiac, intrafemoral, intraprosatatic), castration, oral gavage, maintenance of transgenic colonies, administration of specialized diets, tumor measurements and blood draws. The highly trained and experienced MTMR technical staff provide expertise in the use of in vivo models, and consolidated breeding colonies to ultimately provide high quality service at a significant cost savings to investigators. MTMR is comprised of two technicians who provide technical expertise and perform all services and two research scientists that provide oversight of operations and scientific consultation and budgetary evaluation. First priority for use is given to peer-review-funded RPCI CCSG members;second priority to non-peer-review-funded CCSG members;third priority to non-members and academic collaborators;and last priority to external users. During the reporting period, the Mouse Tumor Model Shared Resource has served 30 members from 5 research programs, with 66% utilization by CCSG members with peer reviewed funding. The CCSG support provides 18% of the overall proposed budget

Public Health Relevance

Animal models of human cancer are a vital resource in the quest to understand, prevent and cure cancer. The Mouse Tumor Model Resource provides the research community with a highly skilled staff and expertise in the appropriate use of animal models. The services provided by the Resource facilitate discovery in cancer biology and the rapid translation of bench science into in vivo studies which compliment translational clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738385
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$71,552
Indirect Cost
$28,302
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Nesher, Elimelech; Safina, Alfiya; Aljahdali, Ieman et al. (2018) Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Res 78:1431-1443
Verma, Aparajita; Rich, Laurie J; Vincent-Chong, Vui King et al. (2018) Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer. J Oral Pathol Med 47:484-491
Sheffer, Christine E; Miller, Austin; Bickel, Warren K et al. (2018) The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors. Cancer 124:4711-4719
Szender, J Brian; Kaur, Jasmine; Clayback, Katherine et al. (2018) Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer 28:26-33
Azad, T; Janse van Rensburg, H J; Lightbody, E D et al. (2018) A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat Commun 9:1061
Buas, Matthew F; Li, Christopher I; Anderson, Garnet L et al. (2018) Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. Cancer Epidemiol 56:83-89
Chung, Sejin; Vail, Paris J; Witkiewicz, Agnieszka K et al. (2018) Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res :
Eng, Diana G; Kaverina, Natalya V; Schneider, Remington R S et al. (2018) Detection of renin lineage cell transdifferentiation to podocytes in the kidney glomerulus with dual lineage tracing. Kidney Int 93:1240-1246
Ling, Xiang; Wu, Wenjie; Fan, Chuandong et al. (2018) An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res 37:240
Sandlesh, Poorva; Juang, Thierry; Safina, Alfiya et al. (2018) Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene. PLoS One 13:e0199785

Showing the most recent 10 out of 1555 publications